Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion

Status unconfirmed · Not applicable

Conditions studied: Empyema, Pleural Effusion

In brief

The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strategies compared with saline placebo.

Key facts

Study ID

NCT00103766

Run by

O'Brien, Jeana D., MD, FACP, FCCP

People needed

75

Starts

2004-10-01

Last updated by the study team

2006-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent
• Age greater or equal to 18 yrs
• Presence of empyema or CPE

You may not qualify if…

• Active internal bleeding
• Pregnancy
• Prior enrollment in this study
• Platelet count less than 100,000/mm3
• Use of warfarin sodium if INR is greater than 1.7
• Use of heparin unless the PTT is less than 1.5 times baseline normal
• Known neurological disorders
• Current or pre-existing bleeding dyscrasia
• Known allergy to Alteplase

Where it is running

• Scott and White Memorial Hospital & Clinic — Temple, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.